Migraines? A Local Clinical Trial May Be for You

Print icon

The Hartford HealthCare Headache Center is currently conducting a research study of a home treatment for migraine using self-administered investigational medical device.

The study device is non-invasive and does not require medications intake. Compensation for your time and travel is available. Hartford HealthCare Headache Center medical director Dr. Brian Grosberg is the principle investigator.

Frequently Asked Questions:

Q: What is the purpose of this study?
A: The Relivion™ device used in this research is an investigational external neurostimulation device, comprised of a headset with integrated electrodes. The electrodes come into contact with your scalp, and when activated, it delivers mild electrical stimulation pulses which are intended to interfere with the migraine episode. The purpose of this research is to evaluate whether the Relivion™ device is safe and helpful in alleviating migraine pain. An earlier study demonstrated positive results.

Q: Am I eligible to participate?
A: To be eligible to participate in this study, you must suffer from migraines with or without Aura and be medically cleared by your doctor to take part in this study

Q: If am eligible and choose to participate, what will be my role in the study?
A: For this study, your study doctor will schedule a minimum of three clinic visits with you and in between those visits, 3 periods of home diary headache reports and treatment with the device, as follows:

  • Screening visit: upon giving written consent to take part in this study, Your medical records will be reviewed by your study doctor and you will undergo a physical and neurological examination. You will be given a migraine diary, which you will be asked to fill in for the next 28 days up until your next study visit.
  • Run-In Period: For approximately 4 weeks, you will be asked to complete a Migraine Diary, you will record migraine episodes timing, duration, intensity, use of anti-pain medications and any additional symptoms such as sensitivity to noise or light and nausea.
  • Randomization visit: You will return to the clinic; the study team will review your diary to confirm you remain eligible for the study. If you are found eligible you will be trained on how to use the study device and how to report study outcomes and be released home with the device and a dedicated iPhone. You will be randomly assigned to one of 2 study groups (you cannot choose your study group; you and the study doctor will not know which group you are in):
    • Group A: active treatment at a therapeutic level.
    • Group B: sham/placebo treatment at a non-therapeutic level.
  • Self-Practice Period: In the next 2 weeks you will be asked to experience the use of the device and diary not during a migraine episode at your home or surrounding. If at least one self-practice run was successful, you will be asked to initiate the ‘Treatment Period’.
  • Treatment Period: during this period, you may use the device at your home for treating a minimum 1 and up to 5 migraine episodes, for up to 10 weeks starting from the randomization visit, whichever comes first.
  • Termination visit: At the end of the Treatment Period, or after completing 5 treatments, you will return to the clinic for the last study visit. At this visit your participation in the study will be over.
    You must make sure that you can come to each visit as scheduled and perform the diary reports and device treatment at home.

Q: Will I be paid for taking part in this research?
A: For taking part in this research, you may be paid up to a total of $350. You will receive the payment after you complete the study visits.

To participate, please call or text the study team at 860.463.2528 or HeadacheResearch@hhchealth.org.

 

 


What's New

Pancreatic Cancer

Free Pancreatic Care Webinar June 11

The fourth leading cause of cancer death in both men and women, pancreatic cancer, is an aggressive form of the disease that often exhibits few symptoms until it is advanced. Approximately 57,000 Americans will be diagnosed with it this year, according to the American Cancer Society. About 47,000 will die...

Jeffrey A. Flaks

A Message From Hartford HealthCare CEO Jeffrey Flaks

With the concerns about coronavirus and COVID-19, I want to assure you that Hartford HealthCare is doing everything possible to protect the safety and well-being of the people and the communities we serve, and our team of healthcare providers. Our goal is to be ready and prepared for whatever is...

Quite Smoking

Trying to Quit Smoking? Here’s Some Help

Editor’s note: Initial studies have shown that if you smoke and get COVID-19, you’re 14 times more likely than nonsmokers to require intensive treatment. If you’ve considered stopping smoking, now is a good time. By Ellen Anderson Dornelas, PhD Director, Cancer Care Delivery and Disparities Research Hartford Healthcare Cancer Institute...

Pancreatic Cancer Recovery

How to Manage Pancreatic Cancer Treatment’s Side Effects

A pancreatic cancer survivor is any person who is actively facing pancreatic cancer or has faced it at some point. It could be someone who has completed treatment or a patient actively receiving chemotherapy for a limited or long-term management of their disease. Patients treated with chemotherapy experience a variety...

Breast Cancer Awareness

The New Normal for Breast Cancer Survivors

The word “patient” stems from the Latin word patiens, meaning sufferer. Until recently, a diagnosis of cancer conveyed a sense of victimhood and loss of control, hence labels such as “cancer patient” or “cancer victim.” Despite good intentions, these terms left those with a cancer diagnosis feeling isolated and somehow...